313 related articles for article (PubMed ID: 15124757)
1. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
3. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M; Radue EW; Kappos L; Hartung HP; Hohlfeld R; Sandberg-Wollheim M; Kooijmans-Coutinho MF; Tsao EC; Sandrock AW;
Neurology; 2002 Nov; 59(10):1507-17. PubMed ID: 12451189
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
[TBL] [Abstract][Full Text] [Related]
6. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
7. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
[TBL] [Abstract][Full Text] [Related]
9. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
Lampl C; You X; Limmroth V
Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
[TBL] [Abstract][Full Text] [Related]
10. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
[TBL] [Abstract][Full Text] [Related]
13. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[TBL] [Abstract][Full Text] [Related]
14. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.
Kita M; Goodkin DE; Bacchetti P; Waubant E; Nelson SJ; Majumdar S
Neurology; 2000 May; 54(9):1741-5. PubMed ID: 10802778
[TBL] [Abstract][Full Text] [Related]
15. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
[TBL] [Abstract][Full Text] [Related]
16. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE
Mult Scler; 2011 Mar; 17(3):353-60. PubMed ID: 20965959
[TBL] [Abstract][Full Text] [Related]
17. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
[TBL] [Abstract][Full Text] [Related]
18. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
Bermel RA; You X; Foulds P; Hyde R; Simon JH; Fisher E; Rudick RA
Ann Neurol; 2013 Jan; 73(1):95-103. PubMed ID: 23378325
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Kira J; Ueno Y; Harada N; Hirakata T
Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies to multiple sclerosis treatments.
Rossman HS
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S12-9. PubMed ID: 15253685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
